Real-world study of Cerviron® vaginal ovules in the treatment of cervical lesions of various

etiologies

IZABELLA PETRE[1,2], DANIELA TEODORA SIRBU[3], RAMONA PETRITA[4], ANDREEA-

DENISA TOMA[5], EMA PETA[6] AND FLORENTINA DIMCEVICI-POESINA[6]

[1]Discipline of Obstetrics and Gynecology XII, 'Victor Babes' University of Medicine and

Pharmacy, 300041 Timisoara; [2]University Clinic of Obstetrics and Gynecology, Emergency Clinic

Hospital 'Pius Brinzeu', 300226 Timisoara; [3]Dr Sirbu Daniela Private Practice, 300269 Timisoara;

[4]Biometrics Unit, MDX Research, 300633 Timisoara; [5]Pharmacy Unit of Municipal Hospital 'Dr

Karl Diel' Jimbolia, 305400 Jimbolia; [6]Quality Assurance, Perfect Care Distribution SRL,

Bucharest, Romania

Correspondence to: Mrs Ramona Petrita, Biometrics Unit, MDX Research Romania, 1-3 Vasile

Loichita Street, 300633 Timisoara, Romania

E-mail: ramona.petrita@mdxresearch.eu

Dr Izabella Petre, Discipline of Obstetrics and Gynecology XII, 'Victor Babes' University of

Medicine and Pharmacy, 2 Eftimie Murgu Square, 300041 TimisoaraE-mail:

dr.petreizabella@yahoo.com

Key words: medical device, cervical lesions, cervical mucosa, cervix re-epithelialization degree,

vaginal pH, vaginal pain, vaginal bleeding

Abstract. Cervical lesions can be caused by pathogens, hormonal changes or by cervical

injury. The recommended treatment in all cases is excision. Local re-epithelialization therapy

should be initiated preoperatively and postoperatively. The present study assessed the post-market

performance and tolerability of Cerviron® ovules in the treatment and management of cervical

lesions postoperatively. The study population included 345 participants aged 20-70 years with

either a cervical lesion under treatment or with recent surgical removal of a cervical lesion. The

degree of re-epithelialization of the cervical mucosa was improved in 73.17% of the patients

evaluated during routine colposcopy exams and 92.73% of patients recorded no bleeding. When
adding Cerviron® either as monotherapy or in association with other antimicrobials in
postoperative care of the cervical ectropion, improved postoperative outcomes such as reduced
post-interventional bleeding, stimulation of the granulation tissue, and a superior quality of healing
were observed. The study and its details are registered in *www.clinicaltrials.gov* under ID
NCT05668806.

Introduction

A cervical erosion (or cervical ectropion) can occur for numerous reasons among women of
childbearing age (1). It is considered a benign condition caused by pathogens or induced by
increased exposure of the cervical epithelium to estrogen. Moreover, cervical erosions can be of
traumatic, mechanical etiology, such as intrauterine devices or foreign bodies introduced into the
vagina (2). Its prevalence ranges from 17 to 50% (3,4). The presence of ectropion is detected
especially after the menarche, during pregnancy or with use of the combined oral contraceptive
pill and is very rare in postmenopausal women (5).

Epithelialization of the vaginal mucus and cervix is crucial in the management of cervical
erosions. Acute inflammation of the cervix as a result from direct infection or trauma translates
into several symptoms, such as white to yellow vaginal discharge (predominant symptom caused
by the mucus-secreting glandular epithelium), post-coital or intermenstrual bleeding, dysuria,
pelvic pain, vulvovaginal irritation and dyspareunia (6). Symptomatic women should be screened
for infective agents (7). Cervical ectropion has been associated with both the combined oral
contraceptive pill and intrauterine contraceptive devices as highlighted by the study conducted by
Wright *et al* (4). Concurrently, a number of studies have highlighted that the use of combined oral
contraceptives is highly associated with the development of cervical ectopy, edema and erythema
of the ectopic zone (7-9).

Pathogens such as streptococci, staphylococci, or enterococci can be promoters of acute
inflammation of the cervix and cervical ectropion (10). Cervicitis (inflammation of the cervix) is
often asymptomatic and can cause complications of the upper genital tract with ectopia and
cervical infection by *Chlamidia trachomatis*, *Neisseria gonorrhoeae*, herpes simplex virus, and
cytomegalovirus (11). Some factors involved in the pathogenesis of cervical ectopy involve the
action of estrogen (12). Estrogens influence immune and inflammatory processes, by regulating

chemokines and chemokine receptors. In a previous study by Straub, the complex processes of
inflammation related to estrogen signaling toward immune cell trafficking were studied (13). The
T helper 17 cells producing IL-17 are the main T cells responsible for chronic inflammation. The
cervical epithelium is highly responsive to estrogen production. Mechanistically, it is considered
that estrogens induce apoptosis in cervical cells and also increase gene expression of human
papillomavirus-16 and -18, the two genotypes frequently associated with cervical cancer (14).
Exposure to high levels of estrogen is also linked to an increased risk of breast cancer (15).
Estrogen influences immune and inflammatory processes by modulating the production of pro-
inflammatory cytokines, chemokines and other immune mediators. Specifically, estrogen can
activate pathways that lead to the production of anti-inflammatory cytokines, such as interleukin-
4 (IL-4), and chemokines, such as interferon-γ (IFN-γ) (16). Furthermore, estrogen can inhibit the
production of pro-inflammatory mediators such as tumor necrosis factor (TNF) and IL-6. Estrogen
can also regulate the expression of chemokine receptors on immune cells, which in turn helps
regulate the migration of immune cells to sites of inflammation (17). For example, estrogen can
downregulate the expression of the CCR5 receptor, which is involved in the migration of T cells
to sites of inflammation. Estrogen can also upregulate the expression of the CXCR4 receptor,
which is involved in the migration of macrophages and neutrophils to sites of inflammation (18).

The presence of endocervical columnar epithelium on the ectocervix favors an increased
exposure to infections due to low cell-mediated immunity. In these areas, the subpopulation of T
lymphocytes, namely, T helper cells, CD8 cells, and CD1 lymphocytes are reduced in number
(19). Therefore, the columnar epithelium cells are more susceptible to infections such as
Chlamydia trachomatis or *Neisseria gonorrhoeae* (20). Estrogens are capable of markedly altering
the responses of host cells to microbes. In adolescence, pregnancy, during hormonal contraception,
or during the years of menstruation (mostly in the ovulatory phase), the probability of developing
cervical ectopy is very high, and sometimes goes undetected (5). Furthermore, cervical ectopy
implies further risks of acquiring sexually-transmitted diseases (gonorrhea, chlamydia and human
papilloma virus). In the study conducted by Sanchez *et al* a causal relationship was found between
cervical erosion and bacterial vaginosis that alter the mucosal barrier and decrease defense
mechanisms of the cervix and vagina (21).

An ongoing debate remains of whether ectopy requires a specific treatment. The association
between squamous metaplasia and induction of squamous cell carcinoma of the cervix is well

known. Moreover, the dysplastic cells are more susceptible to carcinogens (22). Notwithstanding

this, according to a recent study conducted by Kleppa *et al*, ectopy may be a biological risk factor

for chlamydia infection and for human immunodeficiency virus (HIV) in adolescents and in young

women (7).

Currently, cryotherapy (cryosurgery) of the cervix is the standard treatment for symptomatic,

benign cervical ectropion (23). Cryosurgery improves the cervical mucus characteristics and

therefore it is recommended in patients with hostile cervical mucus and ectropion (24). Prior to

and after surgery, adjuvant treatments should be promoted with the support of local, re-epithelizing

treatments (25). For example, Belfiore *et al* reported the effectiveness of a topical treatment for

cervical ectropion with 5 mg of deoxyribonucleic acid (26).

Cerviron has a substance content that provides beneficial properties in non-infectious

vulvovaginitis and cervical erosion. The ovule melts in the vaginal mucosa forming a cream that

ensures dispersion of the substances contained and acts as a protective barrier with astringent

effect, favoring the reepithelization of damaged tissue and the restoration of the initial

colpoecosystem without affecting the Doderlein bacilli. The main mechanism of action of the

medical device is the dispersion of the substances in the vagina and the formation of a protective

barrier that accelerates the natural healing process of the damaged epithelium. Performance and safety

data on Cerviron® vaginal ovules have been reported from multiple sources. Three clinical

investigations on Cerviron were reported (NCT04735705, NCT04735718 and NCT05652959

available   at   https://clinicaltrials.gov/ct2/show/NCT04735705;

https://clinicaltrials.gov/ct2/show/NCT04735718;   and

https://clinicaltrials.gov/ct2/show/NCT05652959, respectively) and published articles on

Cerviron® include the characterization of its utility in the management of cervical uterine fibroids

and on vaginal atrophy after surgical treatment and adjuvant radiation therapy for cervical cancer

(27,28). However, previous safety data was limited and included only a restricted, homogenous

population, including 50 participants in study NCT04735705 and only 27 participants in study

NCT04735718.

Cerviron® is a medical device marketed by Perfect Care Distribution in the following countries:

Albania, Latvia, Lithuania, Estonia, Kosovo, Montenegro, Romania, Kuwait, and the United Arab

Emirates. With a complex composition consisting of three topical pharmaceutical products

including hexylresorcinol, collagen and bismuth subgallate, and four phytotherapeutic extracts

including *Calendula officinalis*, *Hydrastis canadensis*, *Thymus vulgaris* extract and *Curcuma longa*, it is intended as adjuvant treatment for the management of cervical lesions and vulvovaginitis.

Materials and methods

Study objectives. The present study was designed as part of the medical device post-marketing clinical follow-up, involving routine care from a variety of clinical practices. The study includes an open-label, multicentric, non-randomized, single-arm, real-world evidence study design. The data were collected between the 20th of May 2021 and 31st of July 2021.

Real-world evidence studies are post-marketing studies bringing valuable information related to the medical devices' safety and performance profiling and a broader understanding of the practice pattern and the clinical outcomes. The rationale of the study was aimed at capturing safety data in a broader, more heterogenous population. Cerviron® vaginal ovules have been used with success in the treatment of acute and chronic vulvovaginitis of mechanical etiology, and in cervical lesions of mechanical origin, but with a limited number of study participants (NCT04735705 and NCT04735718). Real-world evidence studies and clinical trials are complementary. The present study is considered a real-world evidence study as it reflects actual clinical aspects with data collected in the context of routine delivery of care, as opposed to data collected within a clinical trial, where study design controls variability in ways that are not representative of real-world care and outcomes.

The primary objective was to evaluate the tolerability of Cerviron® ovules in the treatment and management of cervical erosions of various etiologies. The secondary objective of this study was the assessment of performance of the medical device by clinical exam and patients' degree of satisfaction related to the use of the medical device.

Study population. The target population included women aged 20 to 70 years with symptomology associated with cervical ectropion of various etiology such as cervix trauma, postpartum injuries, vaginal infections and cervicitis. A total of 345 women were evaluated. A number of patients were treated with Cerviron® ovules as monotherapy (n=210) and other patients were prescribed Cerviron® ovules as an adjuvant in therapeutic schemas containing antibiotics, antivirals and/or anti-inflammatory drugs (n=135). Subjects with a previous history of any malignancy, including

subjects with vulvar, vaginal, or cervical cancer or with undiagnosed abnormal genital bleeding
were excluded.

The study involved 30 Romanian specialist physicians as investigators from 16 institutions
each treating between 6 and 22 patients. The participating clinical practices and their locations are
listed as Table 1. Upon study entry and at 1, 2 and 3 months after the initial visit, participants were
interviewed and received visual cervical examinations by colposcopy. At each visit, participants
received a standardized pelvic exam with placement of a speculum and visualization of the cervix.

Institution	City, Country (Romania)
Clinical Hospital 'Dr Ion Cantacuzino' Bucharest	Bucharest
Hospital MedLife Humanitas Cluj-Napoca	Cluj-Napoca
Medical office of Dr Saleh K. Majed	Craiova
Medical office of Dr Surpanelu Oana	Iasi
Natisan Medical Center	Pitesti
Gynecological office of Dr Rădulescu G. Mihaela Elena	Râmnicu Vâlcea
Medical office of Dr. Popescu	Sibiu
MediBlue Medical Clinic	Iasi
SC Pan Medical SRL	Sibiu
Medical clinic of Dr. Cioata Ionel Trifon	Timisoara
iMED Clinic	Sibiu
Tulcea County Emergency Hospital	Tulcea
Bradmed SRL	Targu Jiu
Gynecological office of Dr Ioana Trotea Targu Jiu	Targu Jiu
Medical office of Obstetrics and Gynecology of Dr Sirbu Daniela SRL	Timisoara
Dr Todorut Florina	Timisoara
Total sites, 16.	

Table 1. Clinical practices and their locations

Prospective data were collected from each patient, such as initial diagnosis, colposcopy
examination results, re-epithelialization degree, vaginal pH value, vaginal symptoms, any
worsening symptoms and adverse events.

Ethical and regulatory aspects of the study. Written consent for study participation was collected
from all patients. General Data Protection Regulation (GDPR) consent forms were collected from
all patients. Due to legal considerations (GDPR directive effective from 21 May 2018 in all
European Union countries), patients or their legal representatives have an absolute right to request
that their data be removed from the study database. A Notified Body (ENTE CERTIFICATIONE
MACCHINE SRL) reviewed the post marketing clinical follow-up plan, including ethical
considerations. As this is a post-marketing clinical follow-up study, an Ethics Committee approval
was not required, as per the regulations described below.

The study was conducted in accordance with the Guide to medical devices: 'Post-market
clinical follow-up studies'
(https://www.imdrf.org/sites/default/files/docs/imdrf/final/technical/imdrf-tech-210325-
wng65.pdf) and the International Society for Pharmacoepidemiology (ISPE; 2015) Guidelines for
'Good pharmacoepidemiology practices (GPP)'
(https://www.pharmacoepi.org/resources/policies/guidelines-08027/)

The collected data and study procedures were conducted in accordance with the ethical
principles that have their origin in the Declaration of Helsinki.

The study followed the definition of the non-interventional (observational) study provided by
the Guide to Good Pharmacovigilance Practices (GVP; 2017): Module VIII - Post-authorization
safety studies (https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-
pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf).
The study followed the nature of the non-interventional (observational) studies mentioned in the
ICH Harmonized Tripartite Guide Pharmacovigilance Planning E2E (ICH, 2004;
https://database.ich.org/sites/default/files/E2E_Guideline.pdf).

Revision risk analysis was carried out in accordance with the medical device regulation,
available from: https://www.anm.ro/en/dispozitive-medicale/regulamentele-europene-privind-
dispozitivele-medicale. Data were stored according to Annex E of ISO 14155:2020
(https://www.iso.org/standard/). The study and its details are registered in *www.clinicaltrials.gov*
under ID NCT05668806.

Statistical consideration. All statistical analyses were performed using the Excel Analysis

ToolPak, version 16.69.1, from Microsoft. P<0.05 was considered to indicate a statistically

significant difference.

The quality and completeness of the collected data were preliminarily assessed in comparison with

data analysis. No study participant was involved in any violation of inclusion/exclusion criteria.

To examine the treatment significance over time, Fisher's exact test was performed for categorical

variables, and Mann-Whitney U test was employed to perform comparative analysis for variables

non-normally distributed.

Results

Range of gynecological conditions and medical history of selected patients. The selected patients

presented with various gynecological conditions consistent with the instructions for the use of the

medical device. Some patients presented with other conditions with similar symptoms. As the

evaluation of the performance of the device was a secondary objective, other conditions that would

enable further investigations for expanding the use of the medical device were also selected (Table

2).

Gynecological condition	Number of patients (n=345) Age, 20-70 years
Anexitis	4
Atypical squamous cells cannot exclude high grade squamous intraepithelial lesion	5
Atypical squamous cells of undetermined significance	39
Cervical dysplasia	7
Cervical ectropion	47
Cervicitis	59
Dyspareunia	6
Endocervicitis	8
Endocervicosis	11
Exocervicitis	61
Low-grade squamous intraepithelial lesions	6
Metroanexitis	2
Negative for intraepithelial lesion or malignancy	2
Ovarian cyst	2
Post Conization	10
Uterine fibroids	1
Uterus filaments	1
Vaginal atrophy	2
Vaginal polyps	1
Vaginal prolapse	1
Vulvovaginitis	70

Table 2. Medical history of selected patients

Subjects were followed undergoing treatment with Cerviron® vaginal ovules for ~3 months. Each

enrolled subject visited the clinic four times, at 30-day intervals each. The study visit scheme is

listed in figure 1. In the monotherapy group, 11 patients (5.23%) were considered dropouts due to

the fact that they did not attend all the study visits and could not be evaluated. In the polytherapy

group, 32 patients (23.7%) were considered dropouts (figure 1).

Figure 1. Schematic diagram for the present study.

Primary objectives. The study primary objective was to assess the tolerability of the medical device by the number of possible adverse reactions observed during the treatment. In one patient treated exclusively with Cerviron® ovules, during the routine gynecological examination one adverse reaction was noted, which was erythema. The erythema was followed by itching and abnormal vaginal discharge. The investigators determined that this was not related to treatment with the medical device. At the following visit, the reaction was absent.

Two other patients received combined treatment with antibiotics and Cerviron® ovules. After 30 days, both patients reported an adverse reaction of itching and erythema. Investigators determined that the symptoms were consistent with the initial diagnosis. After 60 days, these reactions were absent in both patients. All the aforementioned incidents were linked to preexisting conditions and the investigators decided that they must not be regarded as adverse reactions to the medical device Cerviron®.

Secondary objectives

Clinical performance assessed by the investigator by colposcopy. A significant proportion of 69.14% patients were rated with the indicator 'normal aspect' during colposcopy, as shown in figure 2.

Colposcopic aspect of the cervix

30.86%

69.14%

■ Normal aspect ■ Abnormal aspect

Figure 2. Clinical performance assessed by the investigator by colposcopy

Re-epithelialization degree of the cervical mucosa by gynecological examination. For only 302 patients out of 345, medical records evaluating the degree of epithelialization of the cervical mucosa were available. At the initial visit, 302 participants were assessed, of which 3.64% were rated with 'complete epithelization', 40.40% were rated with degree of 'partial re-epithelialization' and 55,96% were rated with 'absent, ulcerations present'. At 30 days, 47.68% of the 302 women assessed, had a favorable degree of re-epithelialization, with only 4.30% rated as 'absent, ulcerations present'. After 3 months, 73.17% of the 287 patients were rated with 'complete epithelization', as shown in table 3.

Degree of re-epithelialization	Initial evaluation	At 30 days	At 90 days
Absent	169 (55.96%)	13 (4.30%)	6 (2.09%)
Partial	122 (40.40%)	145 (48.01%)	71 (24.74%)
Complete	11 (3.64%)	144 (47.68%)	210 (73.17%)
Total (N)	302	302	287

Table 3. Degree of re-epithelization at initial evaluation, 30 and 90 days.

Vaginal pH level evaluation. It was observed that following a 3-month treatment with Cerviron®, 87.86% of the patients presented with a normal pH, as revealed in figure 3.

Figure 3. Changes in vaginal pH throughout the study (90 days).

Evaluation of the level of pain. Of the total number (n=302) of patients examined at visit 1, 46.67%
reported mild pain levels and 28.00% had no pain at all. At the second visit, 68.49% of the
population (207) rated pain severity as no pain or mild severity in 26.71%. A very high proportion
(86.47%) was pain free at the last visit after 3 months of treatment with Cerviron® (as shown in
figure 4). Figure 4 also provides the corresponding data related to pain level across the treatment
period.

Figure 4. Evaluation of pain level between the study visits (90 days).

Evaluation of the level of vaginal bleeding. At the first visit, 302 women included in the study
were evaluated, of whom 48.70% reported no bleeding observed after treatment with Cerviron®
and 33.91% reported low amounts of vaginal bleeding. The efficacy of medical device was more
clearly observed at visit 2, where 77.68% of patients experienced no bleeding at all and 1.79%

experienced moderate or severe bleeding. After 3 months of treatment, this improvement was noteworthy when 92.73% of patients reported no bleeding and only 7.27% of patients reported a mild level of bleeding, as observed in figure 5.

Figure 5. Evaluation of the level of vaginal bleeding throughout the study (90 days).

Degree of satisfaction after using Cerviron® ovules. In terms of degree of satisfaction offered, participants in the largest population (72.25%) were reported to be 'very satisfied' with the medical device. The degree of satisfaction was measured by a 5-point Likert scale, as revealed in figure 6. (30).

Figure 6. Likert Scale evaluation at the end of the study.

Discussion

A very important aspect that influences the management of cervical ectopy is age. Cervical
ectopy is predominant in young adolescents, with a prevalence of up to 80% in sexually active
adolescents. (31) However, factors associated with the evolution and devolution of cervical ectopy
are diverse and mechanisms have yet to be elucidated. Since ectopy is observed frequently in
adolescent girls and pregnant women, it may vary in response to hormonal fluctuations observed
in pregnancy and during contraception with combined oral contraceptives (32). Screening for
Chlamydia trachomatis and *Neisseria gonorrhoeae* can prevent a range of gynecological
conditions, such as urethritis, cervicitis, cervical erosions (33). Infection in the lower genital tract
can result in upper genital tract complications, such as pelvic inflammatory diseases, ectopic
pregnancy, chronic pelvic pain, and infertility in asymptomatic women, and transmission of
infection during pregnancy and labor (34).

Cryotherapy (cryosurgery) of the cervix is an effective treatment for symptomatic cervical
ectropion (35). Other surgical techniques have been applied for ablation of the squamocolumnar
junction. Cauterization has been applied for this purpose since 1920, but it involves additional
risks, such as burning lesions if the safeguard plate is not located correctly (36). Some specialists
even consider the cervical ectropion as a normal finding that does not require treatment despite the
red and inflamed appearance of the cervix. However, cervical ectropion is considered as one of the
most common types of chronic cervicitis worldwide (37). Topical treatments for cervical
ectropion, including cervical painting with gentian violet paint or microwave tissue coagulation,
are still widely used (4). Although the debate is still ongoing, a harmonized treatment strategy
would reduce complications of cervical ectropion, such as developing abnormal metaplasia and/or
vaginal infection. Applying an intervention to treat cervical ectopy is recommended, especially
when considering taking preventive action against cervical cancer. Ectopic cells are modified over
time by squamous metaplasia and epithelialization, cervical infection with *Neisseria* gonorrhea or
Chlamidia trachomatis, low pH values or trauma (38). Cerviron® appears to have a very potent
action in rebalancing the vaginal pH. In a previous clinical investigation, NCT04735705, vaginal
pH values measured over 90 days showed that Cerviron® restores altered vaginal pH. The
difference in vaginal pH values between baseline versus 90 days, at a 5% significance level was
statistically significant (P<0.05).

A literature review conducted by Machado *et al* indicated that treatment can be used to relieve
occasional symptoms associated with ectopy, but does not support routine treatment for ectopy
(12).

By contrast, a study conducted by Soares *et al*, showed a positive association between cervical
ectopy and human papillomavirus, HIV, bacterial vaginosis, cervical epithelial atypia, postcoital
bleeding, and desquamative inflammatory vaginitis (39). Recognition of cervical ectopy should
alert the clinician to the possibility of a genital chlamydia infection. Opportunistic screening for
chlamydia in young people should be offered to reduce the prevalence of infection and its sequelae.
Chlamydia trachomatis is the most common bacterial sexually transmitted disease. In women,
chlamydial infection usually presents as cervicitis, which can lead to up to 30 to 50% of pelvic
inflammatory disease episodes. Pelvic inflammatory disease has significant reproductive sequelae,
such as tubal infertility and ectopic pregnancy (40).

The main mechanism of action of the medical device is the dispersion of the substances in the
vagina and the formation of a protective barrier that accelerates the natural healing process of the
damaged epithelium. The effect of the medical device is obtained due to the presence of the
Bismuth subgallate and vegetable collagen. Bismuth subgallate is an insoluble solution, with a
very low bio-availability which will create a physical barrier over the affected area of the vaginal
mucosa and therefore will not allow oxygen and pathogens to come in contact with it. In this way,
the substances create the premises that allow the damaged tissue to heal naturally. The role of
exogenous collagen is to be a " sacrificial substrate" in order to reduce excess metalloproteins that
delay wound healing and to regulate the healing of the damaged tissue (14, 40-43). As such,
Cerviron® supportive therapy may be prescribed in sexually active patients for at least 1-3 months,
during10-15 consecutive days, to prevent these infections.

The findings in the present study revealed that a 90-day treatment (3 treatment sessions of 30 days
each) with Cerviron vaginal ovules was beneficial in providing a complete degree of cervical
epithelialization and reduced the multitude of the vaginal symptoms, including bleeding,
inflammation, malodor, dysuria, dyspareunia, pain and leukorrhea. This result is consistent with
previous clinical studies that included the same medical device, NCT04735705 and NCT04735718
(46).

In conclusion, the findings of the present study revealed that administration of Cerviron®
vaginal ovules provided a complete degree of epithelization in majority of patients attending a 90-

days treatment. Moreover, subjects presenting a high grade of ulceration at the baseline visit,
following treatment with Cerviron® presented a complete degree of epithelization. Cerviron®
ovules are an exceptional adjuvant for acceleration of healing of cervical erosions. They favor the
re-epithelialization of the damaged tissue and restoration of the initial colpo-ecosystem. Their
topical application was observed to be effective in reducing unpleasant symptoms such as vaginal
discharge, pelvic pain, and vaginal bleeding. In terms of adverse events, the medical device is
considered safe. The only contraindication to Cerviron® ovules has been determined as
hypersensitivity to the active substance or to any of the excipients within the medical device.
338

Acknowledgements

We would like to thank Mrs Florentina Liliana Calancea (MDX Research, Timisoara, Romania)
for medical writing and Mr Alexandru Pinta (Labcorp Austria GmbH, Vienna Austria) for support
in data management and statistical analysis.

Funding

Perfect Care Distribution SRL (https://www.perfectcare.ro/), the study sponsor, offered the tested
medical devices and a partial grant support.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author upon
reasonable request.

Authors' contributions

IP, RP and ADT were involved in the study design, methodology and original draft preparation.
IP and DTS performed the data collection and data analysis. RP, ADT and IP were involved in
analysis and interpretation of data. EP and FD-P were involved in manuscript review and editing.
IP, DTS and ADT participated in the interpretation of the study results. FD-P and EP confirm the
authenticity of all the raw data. All authors approved the final version of the manuscript to be
published.

Ethics approval and consent to participate

Only participants that voluntarily provided their written consent to the collection of their study
data were included. The collected data and study procedures were conducted in accordance with

the ethical principles that have their origin in the Declaration of Helsinki. As this is a post-

marketing clinical follow-up study, an Ethics Committee approval was not required, but the study

protocol was approved by a Notified Body, ENTE CERTIFICATIONE MACCHINE SRL.

Patient consent for publication

Not applicable.

Competing interests

FD-P and EP are employed at Perfect Care Distribution SRL. All the other authors declare no

competing interests. The funder Perfect Care Distribution SRL had no role in the design of the

study, or in the collection, analyses, or interpretation of data, or in the writing of the manuscript,

or in the decision to publish the results.

References

1. Wildenberg JC, Yam BL, Langer JE, Jones LP. US of the Nongravid Cervix with
Multimodality Imaging Correlation: Normal Appearance, Pathologic Conditions, and
Diagnostic Pitfalls. Radiographics. 2016 Apr;36(2):596–617.

2. Ferenczy A. Benign Lesions of the Cervix. In: Blaustein A, editor. Pathology of the Female
Genital Tract [Internet]. New York, NY: Springer; 1977 [cited 2022 Nov 22]. p. 124–42.
Available from: https://doi.org/10.1007/978-1-4757-6143-6_6

3. Kuhn L, Denny L, Pollack AE, Wright TC. Prevalence of visible disruption of cervical
epithelium and cervical ectopy in African women using Depo-Provera. Contraception. 1999
Jun;59(6):363–7.

4. Wright KO, Mohammed AS, Salisu-Olatunji O, Kuyinu YA. Cervical Ectropion and Intra-
Uterine Contraceptive Device (IUCD): a five-year retrospective study of family planning
clients of a tertiary health institution in Lagos Nigeria. BMC Res Notes. 2014 Dec 23;7:946.

5. Aggarwal P, Ben Amor A. Cervical Ectropion. In: StatPearls [Internet]. Treasure Island (FL):
StatPearls Publishing; 2023 [cited 2023 Mar 22]. Available from:
http://www.ncbi.nlm.nih.gov/books/NBK560709/

6. Mitchell L, King M, Brillhart H, Goldstein A. Cervical Ectropion May Be a Cause of
Desquamative Inflammatory Vaginitis. Sex Med. 2017 Sep;5(3):e212–4.

7. Kleppa E, Holmen SD, Lillebø K, Kjetland EF, Gundersen SG, Taylor M, et al. Cervical
ectopy: associations with sexually transmitted infections and HIV. A cross-sectional study of
high school students in rural South Africa. Sex Transm Infect. 2015 Mar;91(2):124–9.

8. Goldacre MJ, Loudon N, Watt B, Grant G, Loudon JD, McPherson K, et al. Epidemiology
and clinical significance of cervical erosion in women attending a family planning clinic. Br
Med J. 1978 Mar 25;1(6115):748–50.

9. Dugas LR, Lie L, Plange-Rhule J, Bedu-Addo K, Bovet P, Lambert EV, et al. Gut microbiota,
short chain fatty acids, and obesity across the epidemiologic transition: the METS-
Microbiome study protocol. BMC Public Health. 2018 Aug 6;18(1):978.

10.   Critchlow CW, Wölner-Hanssen P, Eschenbach DA, Kiviat NB, Koutsky LA, Stevens
CE, et al. Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific
cervical infection, smoking, and douching. Am J Obstet Gynecol. 1995 Aug;173(2):534–43.

11.   Ortiz-de la Tabla V, Gutiérrez F. Cervicitis: Etiology, diagnosis and treatment. Enferm
Infecc Microbiol Clin (Engl Ed). 2019 Dec;37(10):661–7.

12.   Machado Junior LC, Dalmaso ASW, Carvalho HB de. Evidence for benefits from
treating cervical ectopy: literature review. Sao Paulo Med J. 2008 Mar;126:132–9.

13.   Straub RH. The Complex Role of Estrogens in Inflammation. Endocrine Reviews. 2007
Aug 1;28(5):521–74.

14.   Curcumin counteracts the proliferative effect of estradiol and induces apoptosis in
cervical cancer cells | SpringerLink [Internet]. [cited 2023 Feb 14]. Available from:
https://link.springer.com/article/10.1007/s11010-010-0606-3

15.   Yue W, Wang JP, Li Y, Fan P, Liu G, Zhang N, et al. Effects of estrogen on breast cancer
development: role of estrogen receptor independent mechanisms. Int J Cancer. 2010 Oct
15;127(8):1748–57.

16.   Kassi E, Moutsatsou P. Estrogen Receptor Signaling and Its Relationship to Cytokines in
Systemic Lupus Erythematosus. J Biomed Biotechnol. 2010;2010:317452.

17.   Chakraborty B, Byemerwa J, Krebs T, Lim F, Chang CY, McDonnell DP. Estrogen
Receptor Signaling in the Immune System. Endocrine Reviews. 2023 Feb 1;44(1):117–41.

18.   Rodriguez-Lara V, Peña-Mirabal E, Baez-Saldaña R, Esparza-Silva AL, García-Zepeda
E, Cerbon Cervantes MA, et al. Estrogen receptor beta and CXCR4/CXCL12 expression:
differences by sex and hormonal status in lung adenocarcinoma. Arch Med Res. 2014
Feb;45(2):158–69.

19.   De Luca Brunori I, Facchini V, Filippeschi M, Battini L, Giusti G, Romani L, et al. Cell-
mediated immunity in the course of cervical ectropion. Clin Exp Obstet Gynecol.
1994;21(2):105–7.

20.   Wang LC, Yu Q, Edwards V, Lin B, Qiu J, Turner JR, et al. Neisseria gonorrhoeae
infects the human endocervix by activating non-muscle myosin II-mediated epithelial
exfoliation. PLoS Pathog. 2017 Apr 13;13(4):e1006269.

21. A S, A R, F C, S O. Cervical erosion as result of infectious vaginitis. European Journal of
Experimental Biology. 2(5):0–0.

22. Çekmez Y, Şanlıkan F, Göçmen A, Vural A, Türkmen SB. Is Cryotherapy Friend or Foe
for Symptomatic Cervical Ectopy? MPP. 2016;25(1):8–11.

23. Yildiz S, Alay I, Eren E, Karaca I, Gultekin G, Kaya C, et al. The impact of cryotherapy
for symptomatic cervical ectropion on female sexual function and quality of life. J Obstet
Gynaecol. 2021 Jul;41(5):815–20.

24. Baram A, Paz GF, Peyser MR, Schachter A, Homonnai ZT. Treatment of cervical
ectropion by cryosurgery: effect on cervical mucus characteristics. Fertil Steril. 1985
Jan;43(1):86–9.

25. Zhu T, Chen Z, Xia Q, Jiang S, Jin Q, Farahani MRD, et al. A suppository for treating
cervical erosion and its preparation method. Clin Exp Obstet Gynecol. 2013;40(3):361–6.

26. Belfiore P, Costa E, De Cantis S, Vassallo R, Marino A. Effectiveness and persistence of
a topical treatment for cervical ectropion with deoxyribonucleic acid. Minerva Ginecol. 2005
Aug;57(4):461–6.

27. Bacalbasa N, Balescu IC. 2022-RA-462-ESGO The effects of Cerviron on vaginal
atrophy after surgically treated and adjuvant radiation therapy for cervical cancer.
International Journal of Gynecologic Cancer [Internet]. 2022 Oct 1 [cited 2023 Jan
25];32(Suppl 2). Available from: https://ijgc.bmj.com/content/32/Suppl_2/A391.1

28. Bacalbasa N, Balescu I, Aloul A, Bohiltea R, Socea B, Ursut B, et al. The role of topic
vaginal products in posthysterectomy vaginal atrophy. Romanian Medical Journal. 2021 Oct
1;LXVIII:344–6.

29. 14:00-17:00. ISO 14971:2007 [Internet]. ISO. [cited 2022 Oct 14]. Available from:
https://www.iso.org/cms/render/live/en/sites/isoorg/contents/data/standard/03/81/38193.html

30. Robinson J. Likert Scale. In: Michalos AC, editor. Encyclopedia of Quality of Life and
Well-Being Research [Internet]. Dordrecht: Springer Netherlands; 2014 [cited 2023 Mar 22].
p. 3620–1. Available from: https://doi.org/10.1007/978-94-007-0753-5_1654

31. Bright PL, Turner AN, Morrison CS, Wong EL, Kwok C, Yacobson I, et al. Hormonal
contraception and area of cervical ectopy: a longitudinal assessment. Contraception. 2011
Nov;84(5):512.

32. Bright PL, Turner AN, Morrison CS, Wong EL, Kwok C, Yacobson I, et al. Hormonal
contraception and area of cervical ectopy: a longitudinal assessment. Contraception. 2011
Nov;84(5):512–9.

33. Pillay J, Wingert A, MacGregor T, Gates M, Vandermeer B, Hartling L. Screening for
chlamydia and/or gonorrhea in primary health care: systematic reviews on effectiveness and
patient preferences. Syst Rev. 2021 Apr 19;10:118.

34.   Senn T. Sexually Transmitted Diseases (STDs). In: Gellman MD, Turner JR, editors.
Encyclopedia of Behavioral Medicine [Internet]. New York, NY: Springer; 2013 [cited 2022
Nov 22]. p. 1782–4. Available from: https://doi.org/10.1007/978-1-4419-1005-9_671

35.   Agah J, Sharifzadeh M, Hosseinzadeh A. Cryotherapy as a Method for Relieving
Symptoms of Cervical Ectopy: A Randomized Clinical Trial. Oman Med J. 2019
Jul;34(4):322–6.

36.   Chen J, Zhou D, Liu Y, Peng J, Li C, Chen W, et al. A comparison between ultrasound
therapy and laser therapy for symptomatic cervical ectopy. Ultrasound Med Biol. 2008
Nov;34(11):1770–4.

37.   Liu Y, Yang K, Wu T, Roberts H, Li J, Tian J, et al. Microwave therapy for cervical
ectropion. Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD006227.

38.   Machado Junior LC, Dalmaso ASW, Carvalho HB de. Evidence for benefits from
treating cervical ectopy: literature review. Sao Paulo Med J. 2008 Mar 6;126(2):132–9.

39.   Soares LC, Braz FLTA, Araújo AR, Oliveira MAP. Association of Sexually Transmitted
Diseases With Cervical Ectopy: A Systematic Review. Sex Transm Dis. 2019 Jul;46(7):452–
7.

40.   Jacobson DL, Peralta L, Graham NMH, Zenilman J. Histologic Development of Cervical
Ectopy: Relationship to Reproductive Hormones. Sexually Transmitted Diseases. 2000
May;27(5):252.

41.   Tramontina VA, Machado MAN, Nogueira Filho G da R, Kim SH, Vizzioli MR, Toledo
S de. Effect of bismuth subgallate (local hemostatic agent) on wound healing in rats.
Histological and histometric findings. Braz Dent J. 2002;13(1):11–6.

42.   Thorisdottir H, Ratnoff OD, Maniglia AJ. Activation of Hageman factor (factor XII) by
bismuth subgallate, a hemostatic agent. J Lab Clin Med. 1988 Oct;112(4):481–6.

43.   Jafari B, Jafari-Sales A, Khaneshpour H, Fatemi S, Pashazadeh M, Al-Snafi AE, et al.
Antibacterial effects of Thymus vulgaris, Mentha pulegium, Crocus sativus and Salvia
officinalis on pathogenic bacteria: A brief review study based on gram-positive and gram-
negative bacteria. Jorjani Biomedicine Journal. 2020 Oct 10;8(3):58–74.

44.   Jafari B, Ahmadizadeh C. The In Vitro Study of Antimicrobial Effect of Marigold
(Calendula officinalis) Extract on Infectious Microorganisms. Electronic Journal of Biology
[Internet]. 2018 Jan 3 [cited 2023 Jan 23];13(4). Available from:
https://ejbio.imedpub.com/abstract/the-in-vitro-study-of-antimicrobial-effect-of-
marigoldrncalendula-officinalis-extract-on-infectious-microorganisms-21459.html

45.   Dai C, Lin J, Li H, Shen Z, Wang Y, Velkov T, et al. The Natural Product Curcumin as
an Antibacterial Agent: Current Achievements and Problems. Antioxidants. 2022
Mar;11(3):459.

46.   Petrita R. Real-World Performance and Safety of Cerviron® Medical Device in the
Treatment of Various Types of Vaginitis. BJSTR. 2022 Nov 22;47(2):38364–73.

Likert Scale Evaluation

- Very satisfied 72.25%
- Satisfied 24.80%
- Neutral 2.95%
- Unsatisfied 0%
- Very unsatisfied 0%